HOME  
  RESEARCH  
  NEONATAL  
  HEALTH  
  BOOKLETS  
  NEWS  
  PSAs  
  ABOUT  
WRI Hospital Partner in Kansas City Plays Key Role in Drug Approval

Cystic Fibrosis patients with the defect G551D mutation may benefit from the FDA's approval of Kalydeco. Kalydeco is the first drug that targets the underlying causes of Cystic Fibrosis. Children’s Mercy Hospital in Kansas City, a partner of WRI, helped trial the drug. For the past seven years, WRI has given $600,000 with 100% of the funds underwiting the drug trial study at Children’s Hospital. Kalydeco represents a major treatment advance for the cystic fibrosis community. In clinical trials patients who took Kalydeco showed:
  • A significant improvement of lung function
  • A significant reduction in sweat chloride to below the diagnostic level for CF
  • Fewer pulmonary exacerbations
  • Patient-reported reduction in respiratory symptoms
  • Improvement in weight gain; and
  • No safety issues

Full FDA Press Release

EMAIL US    info@wrmail.org
CALL US     877.957.7575
FIND US ONLINE   
OUR MISSION
To perpetuate the memory of Will Rogers by promoting and engaging in medical research pertaining to cardio-pulmonary diseases and educating the general public on topics of health and fitness.
http://www.frontporchwebsolutions.com/